Linked Life Data

1531602

Source:http://linkedlifedata.com/resource/pubmed/id/1531602

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1992-3-31
pubmed:abstractText
In recent years, the use of flow cytometry has expanded from its initial research role to include the detection of clinically relevant abnormalities in the nuclear DNA content of tumor cells and variations in cell-growth kinetics. Retrospective studies have shown that DNA ploidy, and possibly the proliferative or S-phase fraction, is a valuable prognostic indicator in patients with gynecologic malignancies, including gestational trophoblastic disease, early- and late-stage ovarian cancer, squamous-cell cervical cancer and its precursor lesions, and endometrial adenocarcinoma. Further prospective studies are needed to establish the exact value of flow cytometry for gynecologic and other tumors. However, the prognostic value of this information certainly will influence the clinical management of patients with these malignancies in the near future.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0890-9091
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
23-8, 31; discussion 31-3
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
The current status of flow cytometry in gynecologic oncology.
pubmed:affiliation
Department of Reproductive Medicine, University of California, San Diego.
pubmed:publicationType
Journal Article, Review